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Abstract
Background: Infectious diseases due to multidrug-resistant bacteria are one of the causes of treatment failures
contributing to an increase in mortality and/or morbidity. In this study, we evaluated the antibacterial potential of
different parts of six medicinal plants namely Alstonia boonei, Ageratum conyzoides, Croton macrostachys, Cassia
obtusifolia, Catharanthus roseus and Paullinia pinnata against a panel of 36 multi-drug resistant (MDR) Gram-
negative and Gram-positive bacteria.
Methods: Minimum Inhibitory Concentration (MIC) and Minimal Bactericidal Concentration (MBC) of the
methanol extracts from different parts of the plants were determined using broth microdilution method;
standard phytochemical methods were used for phytochemical screening.
Results: Several phytochemical classes such as polyphenols, sterols, triterpenes, alkaloids, flavonoids and
saponins were identified in the plant extracts. MIC values obtained ranged from 64 to 1024 μg/mL. Leaves
extract of Catharanthus roseus (86.11 %), Croton macrostachys (83.33 %) and Paullinia pinnata (80.55 %)
displayed the best antibacterial spectra. The lowest MIC value of 64 μg/mL was obtained with the Paullinia
pinnata stems extract and Cassia obtusifolia extract against the strain of Staphylococcus aureus MRSA8. Results
also showed that the tested samples generally displayed bacteriostatic effects with MBC values obtained in
only 3.35 % of the cases where plant extracts were active.
Conclusion: The results obtained at the end of this study demonstrate for the first time the antibacterial
activity of the studied medicinal plants against MDR bacteria. The tested plants could be a reservoir of
molecules to fight against MDR bacterial infections.
Keywords: Cameroon, Gram-negative bacteria, Gram-positive bacteria, Medicinal plant, Multi-drug resistance,
Antibacterial activity
Background
Infectious diseases caused by multidrug-resistant bacteria
are growing steadily and are associated with a significant
attributable mortality [1, 2]. The emergence of multi-drug
resistant (MDR) phenotypes was first linked to nosoco-
mial infections; but nowadays they are increasingly re-
sponsible for community infections and all pathogenic
microorganisms are concerned. In Gram-negative bac-
teria, one of the mechanisms of resistance is the lowering
of intracellular amount of antibacterial substances due to
the presence of the resistance nodulation cell division
(RND)-type efflux pumps. This phenomenon gives possi-
bility to bacteria developing resistance to a wide range of
antibiotics, as well as several biocides [3, 4]. Gram-positive
bacteria are also a major cause of hospitalization; infec-
tions due to Staphylococcus aureus resistant to methicillin
(MRSA) are a major health problem both in hospitals and
community environments [5]. MRSA is responsible for
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80461 severe infections and causing the death of 11,285
patients annually in the United States [6]. One of the
possible ways to overcome this phenomenon of multi-
resistance is the continual search for new antibacterial
molecules active vis-à-vis of MDR bacteria. With regard
to the broad diversity of their secondary metabolites, me-
dicinal plants represent undeniable sources of antibacterial
agents. According to WHO [7], 80 % of people in Africa
have used medicinal plants for their health care; it is
also estimated that among medicines sold worldwide,
30 % contain compounds derived from medicinal plants
[8]. Several African medicinal plants previously investi-
gated for biological potential showed good antibacterial
activities. Some of them include Treculia obovoidea [9],
Albizia adianthifolia Laportea ovalifolia [10], Alchornea
cordifolia, Pennisetum purpureum [11]. In our continuous
search of phytochemicals to combat MDR bacterial
infections, we designed the present study to evaluate the
antimicrobial potential of six Cameroonian medicinal
plants namely Alstonia boonei, Catharanthus roseus,
Ageratum conyzoides, Croton macrostachys, Cassia obtusi-
folia, and Paullinia pinnata vis-à-vis MDR Gram-negative
and Gram-positive phenotypes.
Methods
Plant materials and extraction
Various parts of plant (Table 1) were collected from differ-
ent regions in Cameroon during the month of February
2014. These include Alstonia boonei (leaves and bark),
Catharanthus roseus (leaves and stem), Ageratum
conyzoides (whole plant), Croton macrostachys (leaves),
Cassia obtusifolia (whole plant), and Paullinia pinnata
(leaves and stem). After drying, each part was powdered
and soaked in methanol for 48 h at room temperature,
and then filtered using Whatman filter paper N°1. The
filtrate obtain were concentrated at 50 °C under reduce
pressure in a vacuum to obtain each plant extract.
Preliminary phytochemical screenings
The presence of alkaloids, triterpenes, sterols, flavonoids,
polyphenols and saponins were screened according to
the common phytochemical methods described by
Harborne [12].
Chemicals
Chloramphenicol and ciprofloxacin (Sigma–Aldrich, St.
Quentin Fallavier, France) were used as reference antibiotics
meanwhile p-Iodonitrotetrazolium chloride (INT) was used
as microbial growth indicator.
Bacterial strains and culture media
The studied microorganisms included ATCC (American
Type Culture Collection) and MDR clinical strains of
Gram-negative bacteria (Escherichia coli, Pseudomonas
aeruginosa, Enterobacter aerogenes, Providencia stuartii,
Klebsiella pneumoniae and Enterobacter cloacae) and
Gram-positive bacteria (Staphyloccocus aureus). Their
bacterial features are summarized in Table 2; they were
maintained at 4 °C on McConkey agar and Mannitol Salt
Agar (MSA) for Gram negative and Gram positive
bacteria respectively, and sub-cultured on Mueller
Hinton Agar (MHA) for 24 h before any test. Mueller
Hinton Broth (MHB) was used for MIC and MBC deter-
minations.
INT colorimetric assay for MIC and MBC determinations
Minimal inhibitory concentrations (MIC) of different
plant extracts were determined using broth microdilu-
tion method described by Kuete et al. [13] with some
modifications [9]. Briefly, plant extracts, chloram-
phenicol and ciprofloxacin were dissolved in
dimethylsufoxide (DMSO)-MHB (10:90) and 100 μL
each solution was added to a 96 wells microplate
containing MHB, then serially diluted two-fold,
followed by adding of 100 μL of inoculum prepared
in MHB. The microplate was sealed and incubated
for 18 h at 37 °C. The final concentration of inocu-
lum was 1.5 ×106 CFU/mL and less than 2.5 % for
DMSO in each well; Wells containing DMSO 2.5 %
and inoculums were used as negative control whereas
chloramphenicol and ciprofloxacin consist of positive
control. After 18 h incubation, 40 μL of INT
(0.2 mg/mL) was added to each well and re-incubated
for 30 min. MIC was defined as the lowest concentra-
tion of plant extract that inhibited bacterial growth.
The determination of MBC was made by introducing
150 μL of MHB in each well of 96 well plate. Then 50 μL
of the well contents which did not show any growth after
incubation during MIC assays was introduced in the
aforesaid plate accordingly, and incubated at 37 °C for
48 h. The MBC was defined as the lowest concentration
of plant extract, which did not produce a color change
after addition of INT as described previously.
Results
Phytochemical composition
The results of qualitative analysis (Table 3) showed that
plant extracts contain various phytochemical classes of
secondary metabolites. Polyphenols, triterpenes and sa-
ponins were present in all plant extracts except those
from Cassia obtusifolia, Catharanthus roseus leaves and
stem respectively.
In vitro antibacterial effect of plant extract
The methanol extracts from different parts of plants
were tested on 36 bacterial strains including 7 Gram-
positive and 29 Gram-negative bacterial strains. As
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Table 1 Information on plant used in the present study
Plant family/Plant sample -
Herbarium voucher number
Traditional use Part used in
this study
Potential active compounds characterized Previously screened activity
APOCYNACEAE/Alstonia
boonei De Wild – 43368/
HNC
Fever, painful micturition, insomnia,
chronic diarrhea, rheumatic pains,
anti-venom (snake bites), malaria,
diabetes, helminths, arthritis [28, 29].
Leaves, bark Echitamine, echitamidine, Voacangine, akuammidine,





roseus L. – 5689/HNC.
Bleeding arresting, diabetes, fever,
rheumatism, cancer [20, 33].
Leaves, stem Vincristine, vinblastine, benzoic acid, p-hydroxybenzoic acid,
salicylic acid, 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic
acid, 3,4-dihydroxybenzoic acid, 3,5-dihydroxybenzoic acid,
gallic acid, vanillic acid, chlorogenic acid, kaemferol
trisaccharides, Quercetin trisaccharides, Syringetin
glycosides [20, 34].
Wound-healing, antimicrobial,
hypoglycemic, antioxidant [18, 20, 33].
ASTERACEAE/Ageratum
conyzoïdes Linn. – 19050/
SFR-Cam
Purgative, fever, ulcers, wound, mental,
infectious diseases, headaches,
anti-inflammatory, diarrhea [35, 36].
Whole plant β-caryophyllene, precocene I, friedelin, Lycopsamine, echinatine,
β-sitosterol, stigmasterol, 5-methoxynobiletin, linderoflavone B,
eupalestin, sabinene, α and β pinene, β-phellandrene,













lupeol, lupenone, betulinic acid, 28-O-acetylbetulin, betulin,
lupeol acetate, zeorin, benzoic acid, methyl gallate, methyl 2,
4-dihydroxy-3,6-dimethylbenzoate, lichexanthone, β-sitosterol,
and β-sitosterol palmitate, stigmasterol, botulin, crotepoxide [42, 43].
Antimicrobial, antimalarial,
cytotoxic [38, 39, 41].
FABACEAE/Cassia obtusifolia
L. – 39847/HNC
Laxative, eye infections, diarrhea,
urinary tract infections, gingivitis,
fever, cough [25].
Whole plant aloe-emodin, 1-methylaurantio-obtusin-2-O-β-D-glucopyranoside,












acid, physcion, questin, 1,3-dihydroxy-8-methylanthraquinone,
chrysophanol- 10,10′-bianthrone, torosachrysone [44].
Antibacterial, antifungal, mosquito
larvicidal activity, platelet antiaggregatory,
neuroprotective [25, 45–47].
SAPINDACEAE/Paullinia
pinnata L. – 10702/
SRF-Cam
Malaria, erectile dysfunction [24]. Leaves, stem Paullinoside A, paullinomides A and B, β-amyrin, 13β,
17β-dihydroxy-28-norolean-12-ene, β-sitosterol glucopyranoside,
2-O-methyl-L-chiro-inositol, L-quebrachitol, β-sitosterol, friedelin,
daucosterol, aridanin, lotoidoside [24, 48].
Antiparasitic, antimicrobial,
cytotoxic [24, 38, 49].


















shown in Table 4, extracts from leaves of Alstonia
bonnei, Paullinia pinnata and Catharanthus roseus dis-
played wide spectra of activity in comparison to those
from bark and stems of the same plants. The various
plant extracts (when they were active) had MIC between
64 and 1024 μg/mL. Leaves of Catharanthus roseus
showed the best spectrum of activity, inhibiting the
growth of 86.11 % (31/36) of the bacteria (24/29 Gram-
negative bacteria and 7/7 Gram-positive bacteria). The
leaves extract of Croton macrostachys also had an inter-
esting activity (30/36; 83.33 %), followed by extract of
the leaves of P. pinnata (29/36; 80.55 %) and the whole
plant extract of A. conyzoides (25/36; 69.44 %). The
lowest MIC value of 64 μg/mL was obtained with the
Paullinia pinnata stems extract and Cassia obtusifolia
extract against the strain of Staphylococcus aureus
MRSA8. In general, analysis of results shows that MBCs
were obtained in 3.35 % (7/209) of cases where plant ex-
tracts were active.
Discussion
Several classes of secondary metabolites such as alka-
loids, triterpenes, sterols, flavonoids, polyphenols and sa-
ponins have been reported to have antibacterial
properties [13–15]. Their presence in the studied plant
extracts could explain the antibacterial effects of the
tested samples. The need to find new molecules from
medicinal plants with effective mechanisms of action
against the multidrug-resistant phenotype is a necessity
nowadays. All plants used in traditional medicine which
have MIC values less than 8 mg/mL are considered
active [16]. A plant extract has significant antibacterial




AG100 Wild-type E. coli K-12 [50]
AG100A AG100 ΔacrAB::KANR
AG100ATET ΔacrAB mutant AG100, with
over-expressing acrF gene ; TETR
[50–52]




MC4100 Wild type E. coli [55]
W3110 Wild type E. coli [55, 56]
Enterobacter aerogenes
ATCC13048 Reference strain




EA3 Clinical MDR isolate; CHLR, NORR,
OFXR, SPXR, MOXR, CFTR, ATMR, FEPR
[58, 59]
EA27 Clinical MDR isolate exhibiting
energy-dependent norfloxacin and
chloramphenicol efflux with KANR
AMPR NALR STRR TETR
[58, 59]
EA289 KAN sensitive derivative of EA27 [60]
EA294 EA289 acrA::KANR [60]
EA298 EA 289 tolC::KANR [60]
Enterobacter cloacae
ECCI69 Clinical MDR isolates, CHLR [61]
BM67 Clinical MDR isolates, CHLR [61]
BM47 Clinical MDR isolates, CHLR [61]
Klebsiella pneumoniae
ATCC12296 Reference strain
KP55 Clinical MDR isolate, TETR, AMPR,
ATMR, CEFR
[62]
KP63 Clinical MDR isolate, TETR, CHLR,
AMPR, ATMR
[62]
K24 AcrAB-TolC, Laboratory collection
of UNR-MD1, University of
Marseille, France
[61]
K2 AcrAB-TolC, Laboratory collection




NEA16 Clinical MDR isolate, AcrAB-TolC [63]
ATCC29916 Clinical MDR isolate, AcrAB-TolC
PS2636 Clinical MDR isolate, AcrAB-TolC
PS299645 Clinical MDR isolate, AcrAB-TolC
Pseudemonas aeruginosa
PA 01 Reference strain
PA 124 MDR clinical isolate [64]
Table 2 Bacterial strains used in this study and their features
(Continued)
S. aureus
ATCC 25923 Reference strain
MRSA 3 Clinical MDR isolate OFXR, KANR,
TETR, ERMR
[65]
MRSA 4 Clinical MDR isolate OFXR, KANR,
CHLR, CIPR
MRSA 6 Clinical MDR isolate OFXR, FLXR,
KANR, TETR, CIPR, IM/CSR
MRSA 8 Clinical MDR isolate OFXR, FLXR,
KANR, ERMR, CIPR, IM/CSR
MRSA 11 Clinical MDR isolate OFXR, KANR,
ERMR, CIPR, IM/CSR
MRSA 12 Clinical MDR isolate OFXR, FLXR,
KANR, ERMR, IM/CSR
AMPR, ATMR, CEFR, CFTR, CHLR, CIPR, ERMR, FEPR, FLXR, IM/CSR, KANR, MOXR,
OFXR, STRR, TETR, Resistance to ampicillin, aztreonam, cephalothin, cefadroxil,
chloramphenicol, Ciprofloxacin, Erythromycin, cefepime, Flomoxef, Imipenem/
Cilastatin sodium, kanamycin, moxalactam, streptomycin, and tetracycline;
MDR multidrug resistant
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activity if MIC is 100 μg/mL, moderate if its MIC is
between 100 and 625 μg/mL and low when MIC is
above 625 μg/mL [17]. Based on the above criteria, it
can be deduced that all tested plants had antibacterial
activity as MIC values below 8 mg/mL were obtained
with each extract on at least one bacterial strain.
MIC values above 625 μg/mL were obtained with ex-
tract from A. boonei bark against 2/36 (5.5 %) tested
bacteria as well as with C. roseus stem extract against
6/36 (16.7 %) microorganisms tested, indicating that
they rather displayed low antibacterial effects. None-
theless, the activity obtained with the Paullinia
pinnata stems extract and Cassia obtusifolia extract
against the strain of Staphylococcus aureus MRSA8
(MIC value of 64 μg/mL) could be considered import-
ant. Moderate activity was obtained in many cases. In
fact, MIC values ranged from 128 to 512 μg/mL were
obtained with extract from A. conyzoides (whole
plant) against 12/36 (33.3 %) tested bacteria, A. boo-
nei leaves against 19/36 (52.8 %), C. obtusifolia (whole
plant) against 17/36 (47.2 %), C. roseus leaves against
18/36 (50 %), C. macrostachys (leaves) against 25/36
(69.4 %), and P. pinnata stem and leaves against 13/
36 (36.1 %) and 19/36 (52.8 %) respectively.
Though the antibacterial activities of some of the tested
plants have already been reported, their effects against
MDR phenotypes are being documented for the first time.
The extract from the leaves of C. roseus had a broad anti-
bacterial activity (31/36; 86.11 %); Nayak and Pereira [18]
and Kamaraj et al. [19] reported the antibacterial activity
of this plant extract on some sensitive bacteria. Several al-
kaloids were isolated from this plant [20, 21] and these
compounds could also be responsible for the antibacterial
activity of this plant [22]. MIC values obtained with ex-
tract of leaves of C. macrostachys are between 128 and
1024 μg/mL; Antibacterial compounds previously isolated
from this plant include the triterpenoid, lupeol [23]. The
extract of P. pinnata possessed a good activity (MIC of
64 μg/mL) against S. aureus MRSA8 while the extract
from the leaves was active against 80.55 % (29/36) of the
studied microorganisms. Lunga et al. [24] demonstrated
the activity of this plant on strains of Salmonella sp. with
a bacteriostatic effect, corroborating our findings. The ex-
tract of C. obtusifolia significantly inhibited the growth of
S. aureus MRSA8 with MIC of 64 μg/mL, and was active
on 22 of the 36 tested microorganisms. The activity ob-
tained in this study is much better than that mentioned by
Doughari et al. [25]. In fact, they obtained MIC of
2000 μg/mL and 1000 μg/mL on clinical isolate of S.
aureus and P. aeruginosa respectively. This could be due
to the difference of phytochemical composition as the en-
vironmental conditions influence the availability as well as
the amounts of some secondary metabolites in the plant.
One of the best suited secondary metabolite from this
plant is emodin (anthraquinone) which possesses a good
antibacterial activity against S. aureus [26]; this could ex-
plain the interesting activity observed vis-à-vis of MRSA
in this study. The extract of A. conyzoides had a relatively
low activity on all studied microorganisms. Nevertheless,
MIC of 256 μg/mL vis-a-vis E. aerogenes EA-CM64 and
EA27, P. stuartii PS2636, S. aureus MRSA 4 which are
multi-drug resistant clinical strains were obtained; this
could explain the use of this plant in traditional medicine.
Leaves and bark extracts of A. bonnei had a moderate
activity against Gram-negative bacteria whilst bark ex-
tract was not active against Gram-positive species;
this is explained by the fact that some antimicrobial
compounds have specific activity spectrum (narrow)
and therefore will not be active on certain categories
or certain species of microorganisms [27]. Though
the overall activity of the tested plants can be consid-
ered moderate, the results of this study are interesting
taking in account the fact that most of the tested
bacterial strains were MDR phenotypes.
Table 3 Extraction yields and phytochemical composition of the plant extracts
Plant extract (used part) Extraction yield (%) Phytochemicals groups
Alkaloids Triterpenes Sterols Flavonoids Polyphenols Saponins
A. boonei (leaves) 15.8 % - - + - + +
A. boonei (bark) 9.65 % + + + + + +
A. conyzoïdes (whole plant) 8.52 % - + + - - +
C. macrostachys (Leaves) 12.72 % - + + - + +
C. obtusifolia (whole plant) 7.11 % + + + + + +
C. roseus (leaves) 6.89 % + - + + + +
C. roseus (stem) 4.23 % + + + + + -
P. pinnata (leaves) 10.84 % - + + - + +
P. pinnata (stem) 5.47 % - + + - + +
+: presence; −: absence
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Table 4 MIC and MBC (in bracket) of plant extracts and reference drugs
A. conyzoïdes
(whole plant)
A. boonei C. obtusifolia
(whole plant)
C. roseus C. macrostachys
(leaves)
P. pinnata Reference drugs
Leaves Bark Leaves Stem Leaves (Stem) Chloramphenicol
Escherichia coli
ATCC8739 - 512 (−) - - 512 (−) - 512 (−) 1024 (−) - 2 (128)
ATCC10536 256 (−) - - - 512 (−) 1024 (−) 256 (−) 128 (−) - <2 (64)
AG100 1024 (−) - - 256 (1024) 1024 (−) - 1024 (−) 256 (−) 128 (−) 8 (128)
AG100A 1024 (−) - - 512 (−) 128 (−) 256 (−) - 256 (−) 256 (−) <2 (128)
AG100ATET 1024 (−) 512 (−) 1024 (−) - 1024 (−) - - - 512 (−) 32 (−)
AG102 512 (−) 512 (−) 1024 (−) - - - 1024 (−) - 256 (−) 64 (−)
MC4100 - - - - 512 (−) 512 (−) 256 (−) 256 (−) 1024 (−) 16 (−)
W311O 1024 (−) - 128 (−) - 512 (−) - 256 (−) 1024 (−) - 2 (−)
Pseudomonas aeruginosa
PA 01 - - - 256 (−) 512 (−) 256 (−) 256 (−) 256 (−) 1024 (−) 32 (−)
PA 124 - - - - - - - - - 128 (−)
Enterobacter aerogenes
ATCC13048 1024 (−) 512 (−) - 512 (−) - - 128 (−) - - 4 (32)
EA-CM64 256 (−) - - 512 (−) 1024 (−) - 256 (−) 512 (−) 1024 (−) 256 (−)
EA3 - - - - 256 (−) 1024 (−) 128 (−) - - 256 (−)
EA27 256 (−) 512 (−) 512 (−) 512 (1024) 512 (−) 1024 (−) 512 (−) 512 (−) - 32 (−)
EA289 512 (−) 1024 (−) 1024 (−) 256 (−) 512 (−) 1024 (−) 512 (−) 512 (−) 512 (−) 64 (−)
EA298 1024 (−) - 1024 (−) 512 (−) 1024 (−) 1024 (−) 128 (−) 512 (−) 512 (−) 128
Providencia stuartii
NEA16 1024 (−) 512 (−) 1024 (−) 1024 1024 (−) - 1024 (−) 1024 (−) 1024 (−) 32 (256)
ATCC29916 512 (−) 512 (−) - - - - 256 (−) 1024 (−) - 16 (256)
PS2636 256 (−) - - - - 256 (−) 256 (−) 256 (−) - 16 (256)
PS299645 1024 (−) 512 (−) - - 256 (−) 512 (−) 512 (−) 512 (−) - 64 (−)
Klebsiella pneumoniae
ATCC11296 512 (−) 512 (−) 1024 (−) 1024 (−) 1024 (−) 1024 (−) 512 (−) 1024 (−) - 8 (256)
KP55 512 (−) 512 (−) - 256 (−) 512 (−) - 256 (−) 1024 (−) 256 (−) 32 (256)
KP63 1024 (−) 1024 (−) - 1024 (−) 512 (−) - - 1024 (−) 1024 (−) 32 (−)
K24 1024 (−) 512 (−) 1024 (−) 1024 (−) 1024 (−) - 512 (−) 512 (−) - 64 (256)


















Table 4 MIC and MBC (in bracket) of plant extracts and reference drugs (Continued)
Enterobacter cloacae
ECCI69 - 1024 (−) 1024 (−) 1024 (−) 1024 (−) - 1024 (−) 512 (−) 1024 (−) -
BM47 - - - - 1024 (−) - 512 (−) 1024 (−) 1024 (−) 256 (−)
BM67 512 (−) 512 (−) 1024 (−) 512 (−) 256 (−) - 256 (−) 1024 (−) - -
BM94 1024 (−) 512 (−) 1024 (−) 512 (−) 512 (−) - 512 (−) 1024 (−) - 128 (−)
Staphyloccocus aureus Ciprofloxacin
ATCC25923 512 (−) 256 (−) - 256 (1024) 512 (−) 1024 (−) 256 (−) 256 (−) 128 (1024) 2 (8)
MRSA 3 - - - - 1024 (−) - - - - 32 (128)
MRSA 4 256 (−) 256 (−) - 128 (1024) 512 (−) - 256 (−) 256 (−) 128 (512) 64 (128)
MRSA 6 - 128 (−) - 256 (−) 1024 (−) 512 (−) 512 (−) 256 (−) 256 (−) 64 (128)
MRSA 8 - 128 (−) - 64 (512) 128 (−) 1024 (−) 512 (−) 256 (−) 64 (512) 16 (64)
MRSA 11 1024 (−) - - 512 (−) 1024 (−) 1024 (−) 1024 (−) 512 (−) 512 (−) 128 (256)
MRSA 12 - 128 (−) - 256 (−) 1024 (−) 1024 (−) 512 (−) 256 (−) 256 (−) 32 (32)



















The present study demonstrates that plants studied and
mostly C. macrostachys, C. roseus and P. pinnata con-
tain phytochemicals with valuable antibacterial activities
vis-à-vis multi-drug resistant phenotypes. They could be
used in the management of bacterial infections including
MDR phenotypes.
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